Compare Enveric Biosciences Inc (ENVB) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Huntington Bancshares Incorporated — how do they compare? Enveric Biosciences Inc trades at $1.58 (market cap $6.20M), while Huntington Bancshares Incorporated trades at $17.81 (market cap $35.93B). The key difference: Huntington Bancshares Incorporated is far larger — about 5795.2× Enveric Biosciences Inc's market cap, and Huntington Bancshares Incorporated pays a 3.49% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | HBAN | |
|---|---|---|
Market Cap | $6.20M | $35.93B |
Sector | Health | Financials |
52-Week High | $17.40 | $19.27 |
52-Week Low | $1.27 | $15.02 |
Enterprise Value | $1.30M | — |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
Huntington Bancshares (HBAN) trades at $17.82, up 1.25% recently, with a bullish technical outlook and mixed earnings history. The company reported Q2 2026 EPS of $0.33, missing estimates, but revenue growth to $8.13B in 2025 supports a net income margin of 24.77%. Analysts maintain a consensus price target of $19.78, with 45% recommending Buy, amid concerns over rising deposit costs noted in recent news.
HBAN offers potential upside with a reasonable P/E of 13.68 and dividend yield, but faces risks from expense pressures and competitive banking dynamics. The stock's outlook hinges on execution of its ROTCE target of 18-19% by 2027, balancing growth opportunities with macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
